Zai Lab Ltd
corporate_fare Company Profile
Zai Lab Ltd (NASDAQ:ZLAB) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 18 items for ZLAB at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-11-14, rated 7/10. Across its 18 most recent items scored 7 or higher, the top rating is 8/10, with 7 rated 8 or above. Recent SEC coverage for ZLAB spans 10-Q, 8-K, 144, DEF 14A.
Recent high-impact activity:
- KarXT and VYVGART Hytrulo Win First-Time China NRDL Coverage for 2027
- Zoci Hits 40% Confirmed Response Rate in Hard-to-Treat Neuroendocrine Carcinomas
- Zai Lab 10-Q: Q3 Revenue Falls 7% to $108.2M, Net Loss Widens to $46.1M
- Zai Lab Q3 Revenue Slips 7% as Inventory Write-Down Widens Net Loss to $46.1M
- Zoci-Atezolizumab Doublet Hits 81.8% Response Rate in First-Line SCLC
Financial Snapshot
Short Interest & Short Volume
6.67 days to coverFINRA reported short interest of 8,092,682 shares in ZLAB as of the October 30, 2026 settlement, a 8.5% decrease from the prior period — about 6.7 days to cover at its recent average daily volume. On November 20, 2026, 66.7% of ZLAB volume reported to FINRA trade-reporting facilities was marked short.
Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.